Clinical Trial

A Study of WX390 in Patients With Advanced Solid Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 19, 2024 (before its estimated June 12, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of WX390 in patients with advanced solid tumors. The main questions it aims to answer are: * PFS, OS, DoR at week 48; * antitumor effects at week 24 and week 48. Participants will be treated with WX390 orally, and follow the efficacy and safety evaluation according to the protocol.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-11-02.
Trial Details
NCT Number NCT06117540
Lead Sponsor Shanghai Jiatan Pharmatech Co., Ltd
Conditions Solid Tumor
Enrollment 70 participants
Start Date 2021-05-11
Primary Completion 2025-06-12 (estimated)
Study Completion 2026-06-12 (estimated)
Updated on ClinicalTrials.gov 2024-11-19